UPDATE : Saturday, February 22, 2020
GemVax & KAEL confirms potential tracer effective to reperfusion injury
  • By Constance Williams
  • Published 2017.11.22 15:51
  • Updated 2017.11.22 15:51
  • comments 0

A study conducted by the Seoul National University has confirmed that GV1001 has been shown to protect the heart muscles from reperfusion injury after ischemia, GemVax & KAEL said Wednesday.

A research team, led by Professor Im Chung of the department of thoracic and cardiovascular surgery, has investigated the comparison between GV1001-induced hemorrhage, apoptosis, and inflammatory cytokine levels with the control group in heart tissues collected immediately after administration of various concentrations of GV1001 on the anterior wall of the right ventricle just before inducing cardiac muscle ischemia in white rats.

Ischemia refers to a state of insufficient blood flow to supply oxygen to tissues or organs. In particular, ischemia of significant organs due to atherosclerotic vascular stenosis is a cause of serious diseases such as myocardial infarction and cerebral infarction.

Also, myocardial protection after cardiac arrest, which is essential for cardiac surgery, can cause damage to the myocardium during blood reperfusion, so prevention of reperfusion injury after ischemia is vital.

Currently, there are methods to control the cardiac fluid perfusion pressure and to include calcium or oxygen in the perfusion fluid to protect the heart muscle during cardiac surgery.

The confirmation of the effect of GV1001, which reduces the secretion of inflammatory cytokines, is a valuable study as a drug for myocardial protection in the future.

“In addition to protective effects of reperfusion injury after cardiac ischemia, it has recently been shown to function as a stem cell tracer, to repair the damaged cells of amyloid beta which is the cause of Alzheimer's disease,” said Song Hyung-gon송형곤, CEO of GemVax & KAEL. “The research on neovascularization function of kidney cancer cells is the result of studying various functions of GV1001 through steady R & D investment. Based on this, it is possible to make GemVax as a bio company with contents.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Constance Williams
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top